Phase 2
Completed N=24
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Atopic Dermatitis
Dermatitis, Atopic
Source: ClinicalTrials.gov NCT02595008 ↗
Enrolled (actual)
24
Serious AEs
0.0%
Results posted
Dec 2018
Primary outcomePrimary: Number of Participants With HPA Axis Suppression — 3; 1; 16; 3 Participants
Summary
this study is to evaluate the potential of DSXS to suppress HPA axis function in patients with moderate to severe atopic dermatitis.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With HPA Axis Suppression |
3; 1; 16; 3 | — |
Eligibility Criteria
Inclusion Criteria
- Patients with a definite clinical diagnosis of stable atopic dermatitis
Exclusion Criteria
- Patient is under the age of 2
Data sourced from ClinicalTrials.gov (NCT02595008). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.